3-[3-tert-butylsulfanyl-1-[4-(5-methoxypyrimidin-2-yl)benzyl]-5-(5-methylpyridin-2-ylmethoxy)-1H-indol-2-yl]-2,2-dimethylpropionic acid | 1233114-22-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 3-[3-tert-butylsulfanyl-1-[4-(5-methoxypyrimidin-2-yl)benzyl]-5-(5-methylpyridin-2-ylmethoxy)-1H-indol-2-yl]-2,2-dimethylpropionic acid
• 英文别名: AM-643 free acid；3-[3-tert-butylsulfanyl-1-[[4-(5-methoxypyrimidin-2-yl)phenyl]methyl]-5-[(5-methylpyridin-2-yl)methoxy]indol-2-yl]-2,2-dimethylpropanoic acid
• CAS: 1233114-22-1
• 化学式: C₃₆H₄₀N₄O₄S
• 分子量: 624.804
• InChiKey: XIPYFDKZPWWWGS-UHFFFAOYSA-N

物化性质

• 沸点：
  743.8±60.0 °C(Predicted)
• 密度：
  1.20±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  6.5
• 重原子数：
  45
• 可旋转键数：
  12
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  125
• 氢给体数：
  1
• 氢受体数：
  8

反应信息

• 作为反应物：
  描述：

  3-[3-tert-butylsulfanyl-1-[4-(5-methoxypyrimidin-2-yl)benzyl]-5-(5-methylpyridin-2-ylmethoxy)-1H-indol-2-yl]-2,2-dimethylpropionic acid 在 sodium hydroxide 作用下， 以 乙醇 、 水 为溶剂， 以100%的产率得到sodium 3-[3-tert-butylsulfanyl-1-[4-(5-methoxypyrimidin-2-yl)-benzyl]-5-(5-methyl-pyridin-2-yl-methoxy)-1H-indol-2-yl]-2,2-dimethyl-propionate
  参考文献：
  名称：

  5-Lipoxygenase-activating protein inhibitors. Part 3: 3-{3-tert-Butylsulfanyl-1-[4-(5-methoxy-pyrimidin-2-yl)-benzyl]-5-(5-methyl-pyridin-2-ylmethoxy)-1H-indol-2-yl]-2,2-dimethyl-propionic acid (AM643)—A potent FLAP inhibitor suitable for topical administration

  摘要：

  AM643 (compound 6, 3-{3-tert-butylsulfanyl-1-[4-(5-methoxy-pyrimidin-2-yl)-benzyl]-5-(5-methylpyridin-2-ylmethoxy)-1H-indol-2-yl]-2,2-dimethyl-propionic acid) was identified as a potential candidate for formulation as a topical agent for the treatment of skin disorders involving leukotriene production. Dermal application of 6 using a prototypical vehicle in a murine ear arachidonic acid model showed significant reduction in the concentrations of leukotrienes in mouse skin with concomitant reduction in ear swelling. (C) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2010.06.011
• 作为产物：
  描述：

  甲醇 、 ethyl 3-(3-(tert-butylthio)-1-(4-(5-fluoropyrimidin-2-yl)benzyl)-5-((5-methylpyridin-2-yl)methoxy)-1H-indol-2-yl)-2,2-dimethylpropanoate 在 lithium hydroxide monohydrate 作用下， 以 四氢呋喃 、 水 为溶剂， 以98%的产率得到3-[3-tert-butylsulfanyl-1-[4-(5-methoxypyrimidin-2-yl)benzyl]-5-(5-methylpyridin-2-ylmethoxy)-1H-indol-2-yl]-2,2-dimethylpropionic acid
  参考文献：
  名称：

  5-Lipoxygenase-activating protein inhibitors. Part 3: 3-{3-tert-Butylsulfanyl-1-[4-(5-methoxy-pyrimidin-2-yl)-benzyl]-5-(5-methyl-pyridin-2-ylmethoxy)-1H-indol-2-yl]-2,2-dimethyl-propionic acid (AM643)—A potent FLAP inhibitor suitable for topical administration

  摘要：

  AM643 (compound 6, 3-{3-tert-butylsulfanyl-1-[4-(5-methoxy-pyrimidin-2-yl)-benzyl]-5-(5-methylpyridin-2-ylmethoxy)-1H-indol-2-yl]-2,2-dimethyl-propionic acid) was identified as a potential candidate for formulation as a topical agent for the treatment of skin disorders involving leukotriene production. Dermal application of 6 using a prototypical vehicle in a murine ear arachidonic acid model showed significant reduction in the concentrations of leukotrienes in mouse skin with concomitant reduction in ear swelling. (C) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2010.06.011

文献信息

• DP2 Antagonist and Uses Thereof
  申请人：BRITTAIN Jason Edward

  公开号：US20110034558A1

  公开（公告）日：2011-02-10

  Described herein is the DP 2 antagonist [2′-(3-benzyl-1-ethyl-ureidomethyl)-6-methoxy-4′-trifluoromethyl-biphenyl-3-yl]-acetic acid, or a pharmaceutically acceptable salt thereof. Also described are methods of preparing the DP2 antagonist, or a pharmaceutically acceptable salt thereof. Also described herein are pharmaceutical compositions suitable for administration to a mammal that include the DP 2 antagonist, or a pharmaceutically acceptable salt thereof, and methods of using such pharmaceutical compositions for treating respiratory diseases or conditions, allergic diseases or conditions, inflammatory diseases or conditions, as well as other prostaglandin D 2 -dependent or prostaglandin D 2 -mediated diseases or conditions.

  本文描述了DP2拮抗剂[2'-(3-苄基-1-乙基-脲甲基)-6-甲氧基-4'-三氟甲基-联苯-3-基]-乙酸，或其药用盐。还描述了制备DP2拮抗剂或其药用盐的方法。本文还描述了适合用于哺乳动物的药物组合物，包括DP2拮抗剂或其药用盐，并描述了使用这种药物组合物治疗呼吸道疾病或症状、过敏性疾病或症状、炎症性疾病或症状，以及其他前列腺素D2依赖性或前列腺素D2介导的疾病或症状的方法。
• OPHTHALMIC PHARMACEUTICAL COMPOSITIONS OF DP2 RECEPTOR ANTAGONISTS
  申请人：Hutchinson John Howard

  公开号：US20120184496A1

  公开（公告）日：2012-07-19

  Described herein are ophthalmic pharmaceutical compositions, wherein the ophthalmic pharmaceutical compositions are in a form suitable for administration to an eye of a mammal. Ophthalmic pharmaceutical compositions disclosed herein include at least one DP 2 receptor antagonist compound and are used to treat or prevent ophthalmic diseases or conditions.

  本文描述了眼科药物组合物，其中眼科药物组合物以适合哺乳动物眼部给药的形式存在。本文所披露的眼科药物组合物包括至少一种DP2受体拮抗剂化合物，并用于治疗或预防眼科疾病或状况。
• DP2 ANTAGONIST AND USES THEREOF
  申请人：Brittain Jason Edward

  公开号：US20130053444A1

  公开（公告）日：2013-02-28

  Described herein is the DP 2 anatgonist 2-(3-(2-((tert-butylthio)methyl)-4-(2,2-dimethyl-propionylamino)phenoxy)-4-methoxyphenyl)acetic acid, or a pharmaceutically acceptable salt thereof. Also described are methods of preparing the DP 2 anatgonist, or a pharmaceutically acceptable salt thereof. Also described herein are pharmaceutical compositions suitable for administration to a mammal that include the DP 2 anatgonist, or a pharmaceutically acceptable salt thereof, and methods of using such pharmaceutical compositions for treating respiratory diseases or conditions, allergic diseases or conditions, inflammatory diseases or conditions, as well as other prostaglandin D 2 -dependent or prostaglandin D 2 -mediated diseases or conditions.

  本文描述了DP2拮抗剂2-(3-(2-((叔丁基硫甲基)-4-(2,2-二甲基丙酰胺)苯氧基)-4-甲氧基苯基)乙酸或其药学上可接受的盐。还描述了制备DP2拮抗剂或其药学上可接受的盐的方法。本文还描述了适用于给哺乳动物的药物组合物，包括DP2拮抗剂或其药学上可接受的盐，以及使用这样的药物组合物治疗呼吸道疾病或病症、过敏性疾病或病症、炎症性疾病或病症以及其他前列腺素D2依赖性或前列腺素D2介导的疾病或病症的方法。
• TOPICAL FORMULATIONS OF FLAP INHIBITORS FOR ADMINISTRATION TO AN EYE
  申请人：Amira Pharmaceuticals, Inc.

  公开号：EP2379078A2

  公开（公告）日：2011-10-26
• TOPICAL FORMULATIONS OF FLAP INHIBITORS FOR THE TREATMENT OF DERMATOLOGICAL CONDITIONS
  申请人：Amira Pharmaceuticals, Inc.

  公开号：EP2381945A2

  公开（公告）日：2011-11-02